Cargando…
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study, Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients with advanced solid tumours. Patients received a median of two courses (range 1–5) at one of nine dose...
Autores principales: | Awada, A, Punt, C J A, Piccart, M J, Tellingen, O Van, Manen, L Van, Kerger, J, Groot, Y, Wanders, J, Verweij, J, Wagener, D J Th |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362731/ https://www.ncbi.nlm.nih.gov/pubmed/10188890 http://dx.doi.org/10.1038/sj.bjc.6690232 |
Ejemplares similares
-
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996) -
244. Predictors and Outcomes of Multi-Drug Resistant Gram-Negative Bacteremia in Patients with Solid Tumours
por: Varghese, George M, et al.
Publicado: (2023) -
0976. Similar effect of albumin given either as a rapid bolus or slow infusion in a large animal model of sepsis
por: von Seth, M, et al.
Publicado: (2014) - Matthäus-Passion, BWV 244 /
-
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
por: Ma, J., et al.
Publicado: (1994)